Drug Trial Radar · NCT00483158
First Time in Man Study of Finafloxacin Hydrochloride
Last checked: Nov 19, 2026Latest source record: Jul 29, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Aug 2007
Primary completion
May 2008
Study completion May 2008
Sponsor
- Lead sponsor
- MerLion Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 6, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to study the safety of single doses and multiple doses of Finafloxacin hydrochloride in healthy volunteers. The level of Finafloxacin hydrochloride will be measured in the subjects blood and urine. One part of the study will assess if Finafloxacin hydrochloride eradicates Helicobacter pylori, a stomach bacteria. Another part of the study will assess the activity of the drug in urine.
Conditions
- Helicobacter Infections
- Urinary Tract Infection
Interventions
Finafloxacin hydrochlorideDrug
Tablets, oral single dose and multiple dose once daily for 7d
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of single and multiple oral doses of Finafloxacin HCl by assessing adverse events, physical examinations, clinical chemistry examination, hematology, ECG and urinalysis.Time frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Swiss Pharma Contract Ltd
Basel, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.